A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.”
This study was published in the June 8, 2011 Nature [I.F >35] by Prof. Stoffel M, Trajkovski M and others from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Mechanistic insights into the adverse impact of Anti-cancer drugs induced insulin resistance and T2D: Dexamethasone decreases insulin sensitivity via down regulation of a regulator of insulin receptor, Caveolin-1. This study suggests that Dexamethasone, by down regulating its target gene, it may down regulate the regulator of insulin receptor, caveolin-1. Together, this study elucidates the mechanism by which the anti-cancer drug dexamethasone promotes insulin resistance.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Mechanistic insights into the adverse impact of Anti-cancer drugs induced insulin resistance and T2D: Dexamethasone decreases insulin sensitivity via down regulation of a regulator of insulin receptor, Caveolin-1, Genome-2-Bio-Medicine Discovery center (GBMD), 23/08/2014, 05.58 am, http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
